Home > Newsletters > Drug Industry Daily > FDA Draft Guidance Suggests Primary Endpoint for Clinical Trials of Complicated Abdominal Infections
Drug Industry Daily
Oct. 1, 2012 | Vol. 11 No. 192
FDA Draft Guidance Suggests Primary Endpoint for Clinical Trials of Complicated Abdominal Infections
Clinical trials of drugs to treat complicated intra-abdominal infections (cIAI) should have a primary endpoint of complete resolution of symptoms at 28 days following randomization and the absence of clinical failure, according to an FDA draft guidance.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.